Non- Small Cell Lung Cancer - Pipeline Review, H2 2012


#138046

756pages

Global Markets Direct

$ 2500

In Stock


Non-Small Cell Lung Cancer Pipeline Review, H2 2012

Global Markets Directs, 'Non-Small Cell Lung Cancer Pipeline Review, Global Markets Directs, 'Non-Small Cell Lung Cancer Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Non-Small Cell Lung Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Non-Small Cell Lung Cancer. 

Non-Small Cell Lung Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Non-Small Cell Lung Cancer.
  • A review of the Non-Small Cell Lung Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. 
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Non-Small Cell Lung Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Non-Small Cell Lung Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. 
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Non-Small Cell Lung Cancer pipeline depth and focus of Indication therapeutics. 
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. 
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.